argenx NV ADR Total Liabilities
argenx NV ADR total liabilities. Based on the latest financial reports, argenx NV ADR (ARGX) has total liabilities worth $1.61 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ARGX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of argenx NV ADR (2010–2025)
Total liabilities of argenx NV ADR from 2010 to 2025. This chart illustrates how argenx NV ADR's total liabilities have evolved over time, based on quarterly financial data. Check ARGX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
argenx NV ADR Competitors by Total Liabilities
The table below lists competitors of argenx NV ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nu Holdings Ltd.
F:M1Z
|
Germany | €63.57 Billion |
|
Nike Inc
NYSE:NKE
|
USA | $22.97 Billion |
|
Hess Corporation
NYSE:HES
|
USA | $14.75 Billion |
|
ING Groep N.V
MX:INGN
|
Mexico | MX$1.00 Trillion |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
USA | $62.92 Billion |
|
Ambev SA ADR
NYSE:ABEV
|
USA | $51.94 Billion |
|
Sun Life Financial Inc.
TO:SLF
|
Canada | CA$372.96 Billion |
|
HOLCIM NEW(U.ADR)1/5/SF2
F:HLB
|
Germany | €17.52 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down argenx NV ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of argenx NV ADR.
Liquidity & Leverage Metrics
argenx NV ADR Total Liabilities Ratios Explained
argenx NV ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how argenx NV ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for argenx NV ADR (2010–2025)
The table below shows the annual total liabilities of argenx NV ADR from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.36 Billion | +93.06% |
| 2024-12-31 | $704.24 Million | +58.27% |
| 2023-12-31 | $444.95 Million | +38.80% |
| 2022-12-31 | $320.56 Million | +1.43% |
| 2021-12-31 | $316.05 Million | -47.79% |
| 2020-12-31 | $605.36 Million | +40.84% |
| 2019-12-31 | $429.81 Million | +837.86% |
| 2018-12-31 | $45.83 Million | +47.05% |
| 2017-12-31 | $31.16 Million | -30.11% |
| 2016-12-31 | $44.59 Million | +372.68% |
| 2015-12-31 | $9.43 Million | +11.93% |
| 2014-12-31 | $8.43 Million | +84.50% |
| 2013-12-31 | $4.57 Million | -27.24% |
| 2012-12-31 | $6.28 Million | +55.28% |
| 2011-12-31 | $4.04 Million | +99.26% |
| 2010-12-31 | $2.03 Million | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more